Welcome to our dedicated page for KEWAUNEE SCIENTIFIC /DE/ SEC filings (Ticker: KEQU), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on KEWAUNEE SCIENTIFIC /DE/'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into KEWAUNEE SCIENTIFIC /DE/'s regulatory disclosures and financial reporting.
Kewaunee Scientific Corp. (KEQU) – Form 4 filed 07/28/2025 reports two open-market sales by CFO Donald T. Gardner III on 07/24/2025.
- Sold 2,096 common shares at a weighted avg. $58.34 (range $58.00-$58.97).
- Sold 904 common shares at a weighted avg. $59.18 (range $59.00-$59.45).
- Total shares sold: 3,000; estimated proceeds ≈ $175k.
- Direct ownership dropped from 17,564 to 14,564 shares, a reduction of roughly 17%.
No derivative transactions were reported and the filing offers no commentary on the purpose of the sales.
Kewaunee Scientific Corp. (KEQU) – Form 144 filing: an unidentified insider intends to sell up to 3,000 common shares through Fidelity Brokerage Services on or about 07/23/2025 via Nasdaq. At the recent reference price, the proposed sale is valued at $174,750.
The company has 2,844,290 shares outstanding, so the sale represents roughly 0.1 % of total shares. The seller acquired the stock on 06/23/2023 as a stock-award compensation; no cash purchase was involved, and there have been no other sales in the past three months. The filer certifies that no non-public, material adverse information is known.
While Form 144 notices are routine, any insider disposition can influence sentiment. Given the small size relative to float and absence of other sales, the filing is unlikely to be materially impactful for KEQU’s fundamentals.